Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 2398

Next Previous
X
Search
Drug Profile

HRS 2398

Alternative Names: HRS-2398

Latest Information Update: 03 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 03 Jul 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT06439589) (Shanghai Hengrui Pharmaceutical pipeline, July 2024)
  • 03 Jun 2024 Shanghai Hengrui Pharmaceutical plans to initiate a phase Ib/II trial for Solid tumours (In combination therapy, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT06439589)
  • 10 Jan 2022 Pharmacodynamics data from preclinical studies of HRS 2398 in cancer released by Jiangsu Hengrui Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top